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The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to
survey if current biomarker testing for heart failure (HF) in Europe is in accordance with
up-dated guidelines.
Methods
A web-based questionnaire was distributed to clinical laboratories via European
biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP)
assays performed, decision limits for HF, and opinion concerning requirement of
different thresholds in patients with renal failure or obesity.
Results
There were 347 participating laboratories mostly from European countries with 266
offering NP testing. NP testing was increased from 67% to 77% between 2013 and
2019. NT-proBNP remained the preferred biomarker. Recommended decision limits
were implemented for BNP (85%) and better focused for NT-proBNP (40%) than in the
previous survey. The survey revealed that laboratorians are willing to support the
translation of adjusted cut-off values for age, gender and for patients with conditions
like renal insufficiency.
Conclusion
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Guidelines stimulate clinical laboratories to offer NP testing with high value for the
diagnosis and management of HF, and to present adjusted medical decision limits.
Future guidelines should encourage the use of personalized cut-offs for some
confounding factors.
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Background: The European Federation of Clinical Chemistry and Laboratory Medicine 
(EFLM) initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to 
survey if current biomarker testing for heart failure (HF) in Europe is in accordance with up-
dated guidelines. 
Methods: A web-based questionnaire was distributed to clinical laboratories via European 
biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP) assays 
performed, decision limits for HF, and opinion concerning requirement of different thresholds 
in patients with renal failure or obesity.  
Results: There were 347 participating laboratories mostly from European countries with 266 
offering NP testing. NP testing was increased from 67% to 77% between 2013 and 2019.  NT-
proBNP remained the preferred biomarker. Recommended decision limits were implemented 
for BNP (85%) and better focused for NT-proBNP (40%) than in the previous survey. The 
survey revealed that laboratorians are willing to support the translation of adjusted cut-off 
values for age, gender and for patients with conditions like renal insufficiency.  
Conclusion: Guidelines stimulate clinical laboratories to offer NP testing with high value for 
the diagnosis and management of HF, and to present adjusted medical decision limits. Future 
guidelines should encourage the use of personalized cut-offs for some confounding factors. 
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 NP testing by laboratories substantially increased (10%) between 2013 and 2019 
 NT-proBNP remained the preferred biomarker 
 Decision limits from guidelines were more often used than in the previous survey 
 Laboratorians are willing to support the implementation of adjusted cut-off values  
 73% of participating laboratories have already been accredited/certified 
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Abstract 
Background: The European Federation of Clinical Chemistry and Laboratory Medicine 
(EFLM) initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to 
survey if current biomarker testing for heart failure (HF) in Europe is in accordance with up-
dated guidelines. 
Methods: A web-based questionnaire was distributed to clinical laboratories via European 
biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP) assays 
performed, decision limits for HF, and opinion concerning requirement of different thresholds 
in patients with renal failure or obesity.  
Results: There were 347 participating laboratories mostly from European countries with 266 
offering NP testing. NP testing was increased from 67% to 77% between 2013 and 2019.  NT-
proBNP remained the preferred biomarker. Recommended decision limits were implemented 
for BNP (85%) and better focused for NT-proBNP (40%) than in the previous survey. The 
survey revealed that laboratorians are willing to support the translation of adjusted cut-off 
values for age, gender and for patients with conditions like renal insufficiency.  
Conclusion: Guidelines stimulate clinical laboratories to offer NP testing with high value for 
the diagnosis and management of HF, and to present adjusted medical decision limits. Future 











The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) plays an 
important role in the continuing education of specialists in laboratory medicine and for the 
promotion and dissemination of best practices in clinical laboratories, contributing to evidence-
based medical decision and patient safety [1].  
Biomarkers, and more specifically testing for natriuretic peptides (NP), are important 
components of the diagnosis and management of heart failure (HF). Testing for Natriuretic 
peptides (NP), more precisely for B-type natriuretic peptide (BNP), N-terminal pro B-type 
natriuretic peptide (NT-proBNP) and mid-regional pro A-type Natriuretic Peptide (MR-
proANP), has been incorporated into multiple European and International guidelines because 
of its high value for the clinical setting of heart failure (HF). NP are also becoming important 
companion assays and endpoints to assess the efficiency of new treatments for HF [2,3]. 
The EFLM initiated the CAMARGUE (CArdiac MARker Guideline Uptake in Europe) study 
that aims to monitor the implementation of guidelines encompassing the use of biomarker tests 
for acute coronary syndrome and heart failure (HF) [4-8]. A CAMARGUE follow-up study was 
undertaken in 2019 to monitor the use of biomarker testing in HF, acute coronary 
syndrome and dyslipidaemia and the level of implementation of related guidelines.  
The present article present the results of the 2019 edition of the CAMARGUE survey 





2. Materials and Methods 
A web-based questionnaire was developed by the EFLM TG-CM. The questions focused on 
recent recommendations of the ESC (European Society of Cardiology), at the time of the 
survey [9]. The questionnaire comprises of 27 multiple-choice and free text questions 
regarding heart failure testing, and covered the following topics: analytical methods and 
manufacturer used, reported measurement units, decision threshold for acute and chronic HF, 
opinion concerning different thresholds in obesity or renal failure and quality assurance.  
 
The survey was sent to EFLM National Societies from 40 member countries in spring 2019 
and was accessible between April and August 2019 via web-link. Details of the survey and its 
performance were published previously [4-6]. A total of 347 European and a minority of 
laboratories outside Europe responded with more than 10 answers and were included for 
evaluation. As some respondents did not answer all the questions, some sections of the survey 
had missing data. Therefore, percentage calculations always refer to the responses that 




3. Results  
3.1. Participating laboratories 
In this fourth CARMAGUE survey, 347 participants answered more than ten questions, of 
which a total of 266 laboratories from 33 countries responded to the HF questions (Table 1). 
These laboratories were mostly from Europe (256 laboratories) and a few from other countries 
(4 from USA, 2 from Canada, 1 New Zealand, 1 Argentina, 1 Lebanon, 1 Israel). As in the 
previous questionnaires the majority of laboratories (93%) provided a 24-hour service (95% 
in 2006, 83% in 2009, 93% in 2013).   
 
3.2. Natriuretic Peptides 
NP measurement was provided by 76% (n=266 out of 347) of the responding laboratories, 
which is slightly more than in the previous surveys (67% in 2013, 68% in 2009).  The 
common stated concentration unit was ng/L or pg/mL (95%). NT-proBNP was still the most 
widely used NP assay (79% of laboratories offering an NP; 68% in 2013 survey), and BNP 
was used in 21% (Figure 1A). Twenty (7.5%) laboratories measured more than one NP and 
mostly combined NT-proBNP from Roche with a BNP assay (Figure 1B). There were also 7 
laboratories performing POCT assays (5 Quidel or Alere Triage, 1 Radiometer AQT90 Flex, 1 
not determined). MR-proANP was not commonly used (n=4) and only in laboratories, that 
also measured NT-proBNP.  
 
3.3. Decision limits for acute HF 
We asked, whether a single cut-off value (not reference values) was applied to rule-out acute 
HF. This was agreed in 61% and denied in 39% of respondents answering this yes or no 
question (n=180). Similar to the previous surveys, there was a variety of answers for stating 
the specific cut-off. For NT-proBNP, 40% (n=44/110) used the ESC 2016 guideline conform 
rule-out cut-off of 300 ng/L, 28% stated the 125 ng/L value (n=31/110) and 14% used age or 
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gender dependent values (n=15/110; Figure 2 and 3A). The most commonly utilized decision 
limit for BNP was the ESC 2016 guideline recommended rule-out cut-off of 100 ng/L (85%; 
n=23/27; Figure 3B). 
 
A further question was, whether a single cut-off value was used to rule-in acute HF, which 
was the case in 25% of 161 participants answering this yes or no question. When asking for 
specific cut-offs, several different ones were stated for NT-proBNP with values ranging from 
115 ng/L up to 2000 ng/L. There were 39% (n=86) participants of 223 NT-proBNP users, 
who applied age-dependent cut-off values to rule-in acute HF. However, 52% (n=45/86) of 
these respondents only answered this question only with "yes" with no further information 
concerning values. Nevertheless, most frequently (29%; n=25/86) the ESC recommended cut-
off levels of  >450 ng/L for patients <50 years, >900 ng/L for patients 50-75 years old and 
>1800 ng/L for >75 years old patients were stated. In 6% of laboratories (n=5/86) the two age 
dependent cut-off values from the FDA-cleared package insert were used: 125 ng/L for <75 
years old and 450 ng/L for >75 years old patients. Of all BNP users, 28% provided more 
detailed answers concerning the single rule-in cut-off values for acute HF (n=17/61 of BNP 
users). The most common cut-off of 100 ng/L was utilized in 71% (n=12/17), followed by 
400 ng/L in 12% (n=2/17) and 500 ng/L in 12% (n=2/17). 
 
3.4. Decision limits for chronic HF 
Respondents were asked, whether they reported cut-off values (not reference value) to rule-
out chronic heart failure. Nearly half of 192 respondents answering this yes or no question 
(47%) reported in the affirmative. As extracted from a more specific separate question, the 
NT-proBNP cut-off of 125 ng/L derived from the ESC guidelines was stated in about one 
third (32%; n=23/72), and one fifth (21%; n=15/72) applied 400 ng/L as cut-off value. Several 
participants reported using 125 ng/L for <75 years old and 450 ng/L for >75 years old patients 
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(12%; n=9/72). Further, various other thresholds were stated from different respondents. 
Concerning BNP only two participants responding to this question (n=2/16 of BNP users) 
applied the ESC guideline cut-off value of 35 ng/L. More than half of respondents (63%; 
n=10/16) used 100 ng/L as a cut-off value for ruling-out chronic HF.  
 
3.5.  Opinions of participants 
We were interested in the opinion of laboratorians concerning the application of different cut-
off values in widely discussed topics, but not explicitly stated in the guidelines so far. One 
question addressed the need to provide age-dependent and a further one, gender-dependent 
cut-off values in the guidelines. The majority of respondents would appreciate this, 90% 
(n=152/169) supported age and 80% (n=114/142) gender specific cut-offs. Also more than 
half the respondents (63%; n=82/131) saw a requirement for different cut-off values (not 
reference value) for patients with renal insufficiency suspected of having acute or chronic 
heart failure, with most supporting the implementation of higher cut-off values (90%; 
n=74/82) and only a minority supporting lower ones (10%; n=8/82). In contrast, less than half 
of respondents (40%; n=43/107) saw a benefit in different cut-off values (not reference value) 
for obese patients suspected having acute or chronic heart failure. In this case 72% (n=31/43) 
indicated lower cut-off values, but 30% (n=12/43) higher ones. Since the new HF medication 
Sacubitril/Valsartan (synonyms: angiotensin-receptor-neprilysin-inhibitor/ARNI) has become 
available on the marked, we wanted to corroborate whether the clinicians in the hospitals 
already used it as treatment for HF patients. There were 85 participants responding to this 
question resulting in 93% positive answers (yes: n=79/85; no: n=6/85). 
 
3.6. Quality assurance 
Seventy three percent of laboratories were accredited or certified. Internal and external quality 
assurance was performed by 99% and 92%, respectively, of respondents. Three further 
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questions address the utilization of protocols. In 41% (n=96/237) a rule-out protocol for 
natriuretic peptide was applied, whereas in 45% (n=107/237) not, and 14% were not sure 
about that (n=34/237). The protocol derived from different sources, but the most common one 
was from the ESC guidelines (Figure 4).  
 
4. Discussion 
The value of testing for natriuretic peptides for the diagnosis and management of HF is 
recognized and translated into European and International guidelines. Furthermore, 
measurement of natriuretic peptides became an important endpoint in clinical trials related to 
HF. It is therefore important to assess the implementation of guidelines by clinical laboratories 
into practice and best practices associated to biomarker testing in HF. 
We performed this follow-up CARMAGUE survey in 2019, because the previous one (2013), 
highlighted that there was a large uncertainty concerning which cut-off values should be applied 
to rule in or to rule out patients with acute or chronic HF. At this time, two different ESC 
algorithms were available, published separately in 2012 (Table 2), perhaps contributing to this 
dilemma. The 2016 ESC guidelines were clear and unequivocal for ruling out decision limits 
in acute HF patients and also incorporated a further NP, MR-proANP. The main findings of 
this updated survey are: first, laboratories offering NP testing increased substantially from 67% 
in 2013 to 77% in 2019. Second, NT-proBNP remained the preferred marker (79%), MR-
proANP was rarely used. Third, the recommended medical decision limits for acute HF were 
very well implemented for BNP (85%) and better focused for NT-proBNP (40%) than in the 
previous survey. Fourth, the majority of laboratorians would appreciate specific age-dependent 
(90%) and gender-dependent (80%) cut-off values for HF as well as different cut-off values 
(not reference value) for patients with renal insufficiency (63%) suspected having acute or 
chronic HF. Such a requirement for obese patients was not so well supported in the answers, 
only 40% saw a benefit. Finally, accreditation of laboratories depends on national regulations 
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and is not a prerequisite in many European countries, nevertheless, 73% of respondent 
laboratories had been accredited/certified. Further, there is an appreciated upwards trend of 
performing EQA for NP assays, with nearly all of participating laboratories having such a 
scheme (92% in 2019 vs. 84% in 2013) . 
This survey revealed encouraging data, showing that more than half of respondents applied a 
single cut-off value to rule out acute HF (61%). The new ESC guidelines, published two years 
before the survey was rolled out, were thus very well taken up by laboratorians and increasingly 
implemented in practice. This can be illustrated by a 10fold increase in the use of the 300 ng/L 
cut-off for NT-proBNP (40% in 2019 vs. 4% in 2013) and a nearly doubling in the use of 100 
ng/L cut-off for BNP (85% in 2019 vs. 48% in 2013). However, there were still nearly one third 
of participants who reported a 125 ng/L cut-off for NT-proBNP, which is recommended for 
ruling out chronic HF or derived from the package insert as the medical threshold for patients 
<75 years. At this point, it should be emphasized that the guideline derived cut-off values are 
well established and have achieved a class I recommendation for diagnosis and prognosis for 
several years (Table 2).   
Although the recent guidelines were clear in respect of single decision thresholds for ruling out 
acute or chronic HF, specific higher thresholds for ruling in HF were not clearly addressed. The 
purpose of the relatively low rule out cut-off values was to reach a high negative predictive 
value to safely exclude patients from having HF. For ruling in acute HF higher cut-off values 
may be more practicable in order to save costs that would arise for HF workup in case of mildly 
elevated levels. The ICON-RELOADED (International Collaborative of NT-proBNP Study) 
study verified the formerly reported age-dependent decision limits for NT-proBNP to rule in 
acute HF (450/900/1800 ng/L for <50/50-75/75y) [19], which were moreover, integrated into 
the ESC/HFA position paper and practice guidance published 2019 (Table 2) [18], just when 
the present survey was rolled out. In that position paper also higher cut-offs were recommended 
for BNP. The present survey revealed that indeed a third (29%) of respondents, who applied 
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age-dependent NT-proBNP thresholds to rule in acute HF, used them (450/900/1800 ng/L for 
<50/50-75/75y). However, the recent ESC position paper was probably coincidental with the 
common laboratory practice of using these well-known NT-proBNP thresholds that were 
corroborated by the ICON-RELOADED study in 2018 and stated before in the ESC 
recommendations 2012 (Table 2). We thus recognized an upwards trend of age-dependent rule 
in thresholds in this setting compared to the 2013 survey (29% in 2019 vs. 17% in 2013). 
The ESC position paper states similar cut-offs for ruling out chronic HF as the ESC guidelines 
2016 (BNP <35 ng/L; NT-proBNP <125 ng/L), but, lists slightly higher ones for ruling in 
chronic HF. Only the NICE national clinical guidelines recommend higher cut-off values for 
ruling out chronic HF (BNP <100 ng/L; NT-proBNP <400 ng/L; Table 2), which were found 
to be optimal in UK primary care. In this case, the intention was to avoid unnecessary 
investigations contributing to patient anxiety and potentially overwhelming cardiology services 
due to too low cut-offs. Notably, since 2019 NICE favours NT-proBNP over BNP 
measurement. As far as could be extracted from the present questionnaire, one third of the 
respondents answering the question concerning thresholds to rule out chronic HF used the ESC 
guideline recommended NT-proBNP threshold of 125 ng/L (32%), which is four times more 
often than in the 2013 survey. The NICE threshold was applied in 21% (NT-proBNP 400 ng/L) 
of laboratories and still, the age-dependent threshold of the package insert, already stated for 
acute HF, was used in 12%. For BNP the former NICE threshold was the preferred one in 63% 
of participants answering this question, the ESC guideline recommended cut-off was only used 
in two laboratories. This may be partly explained by a relatively low number of answers to this 
question (n=16 out of 61 BNP users), but could also be due to the use of the package insert 
upper reference limit, which is also 100 ng/L for most BNP assays. Generally, this follow-up 
survey revealed that although there were still various threshold used in laboratory or clinical 
practice, an encouraging shift to guideline recommended thresholds in the acute and chronic 
HF setting were recognized.  
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As renal failure or obesity have been found to influence NP levels, an adaption of the decision 
thresholds of NP was suggested [20-25]. In HF patients with renal failure NP are increased 
compared to those without. There is a significant correlation between glomerular filtration rate 
and both NP, NT-proBNP and BNP [20, 22]. The very recent practical guidance of the Heart 
Failure Association of the ESC therefore, recommends increasing the BNP threshold from 100 
ng/L to 200 ng/L to rule out acute HF [18]. However, a higher threshold may not necessarily 
be required, if age-dependent cut-offs were used to rule in acute HF [18, 26]. Indeed, most of 
the participants of this survey (90%) would appreciate age-dependent cut-off values and more 
than half (52%) stated to use them in case of NT-proBNP. Thus, it can be expected, that the 
recommended thresholds from the ESC practice guidance will rapidly be applied by 
laboratories. Consequently, the impact of renal failure on the threshold values for NT-proBNP, 
but not BNP, may be negligible, because the recommended values seem to be high enough to 
rule in acute HF. Indeed, 63% of respondents effectively saw a benefit of adapted thresholds in 
the presence of renal failure. In contrast, only 40% of respondents deemed it worth having 
different cut-off values in obese patients. That both higher and lower cut offs were suggested 
indicate that laboratorians may be less familiar with the studies indicating that NP 
concentrations will decrease with increasing body mass index [23, 24]. According to the recent 
ESC practice guidance the thresholds should be reduced by 50% in obese patients to be sensitive 
enough for ruling out HF. 
There is an ongoing discussion whether NP are useful biomarkers for HF monitoring, and in 
particular whether BNP can be measured to monitor HF improvement if patients are treated 
with the new dual drug sacubitril-valsartan [27]. This drug is approved for systolic HF with 
reduced ejection fraction and has obviously gained great acceptance; 93% of respondents 
(n=79/85) used this treatment. The uncertainty derived from moderate increased BNP 
concentrations (Siemens assay) in the first weeks after treatment in the PARADIGM-HF trial 
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while NT-proBNP declined [28, 29]. However, by the end of the trial both, BNP and NT-
proBNP concentrations had declined. Therefore, in the long term both NP may show the 
beneficial effects of treatment. Nevertheless, it is still not clear, whether the effects were 
influenced by the elimination of patients who withdraw or died or whether it is due to effects 
on the molecular basis of the peptides circulating as various fragments and for NT-
proBNP/proBNP in differently glycosylated states [30, 31]. Of note, the dynamics of BNP 
measured with different assays were very heterogeneous after sacubitril-valsartan treatment 
[32], which should be further investigated in larger studies. It has to be emphasized, that the 
treatment effect of neprilysin inhibition targets more effectively other peptides than BNP such 
as atrial natriuretic peptide or adrenomedullin. The increasing BNP values may be challenging 
in the first weeks after treatment, but clinicians should be aware, that these increases are rather 
modest and in case of suspicion of acute decompensation of HF, there are more pronounced 
increases of BNP accompanied by clinical symptoms. A biomarker should always be 
interpreted in context with the clinical findings.  
Lastly, our survey highlighted that, even if accreditation of laboratories depends on national 
regulations and is not a prerequisite in many European countries, 73% of laboratories were 
accredited or certified and that internal and external quality assurance was performed by 99% 
and 92%, respectively, of respondents. This demonstrates that NP testing are performed in 
environments with a continuous monitoring of the quality and training of the stakeholders, 
contributing to the reliability and accuracy of the results as well as patient safety. 
 
5. Limitations 
A limitation of this study is that not all laboratories of the countries involved in this survey 
responded. Results might have been different if all clinical laboratories had participated. 
However, a 100% response rate is hard to yield in such surveys. The proportion of different 
laboratory types (university vs. local)  were very similar to those obtained with previous 
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CAMARGUE and other EFLM questionnaires so that we strongly believe that our results may 
reflect the present situation of natriuretic peptide testing in European laboratories. 
 
6. Conclusion 
Testing for natriuretic peptides is of high clinical impact for the diagnosis and management and 
HF. European and international guidelines stimulate clinical laboratories to offer natriuretic 
peptide testing as well as to adopt the recommendations for best practices and use of adjusted 
medical decision limits. Specialists in laboratory medicine are now expecting that guidelines 
provide and encourage the use of more personalized cut-offs for some conditions like renal 
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Table 1: Summary data of the past four questionnaires. 
 NP in EU 
2006 
NP in EU 
2009 
NP in 2013 NP in EU 2019 
EU  North America 
Total participants (n)* 220 303 442 91 347 
Countries 8 39 36 n.a. 33 
Universities/Teaching/Tertiary Care 
(%) 
55 58 50 64 61 
NP participants (%) 56 68 67 58 77 
NP participants (n) 123 206 294 53 266 
Data including only NP participants:  
24 h laboratory service (%) 95 83 93 96 93 
Age or gender related decision limits 
(%)** 






Accreditation/certification (%) n.a. n.a. 69 96 73 
EQA (%) 79 85 84 96 92 
 
* Total number of responses with usable data. ** values for the 2013 EU/North American and the 2019 surveys are summarized percentages of 
acute and chronic heart failure stated separately for BNP and NT-proBNP, respectively. 






Table 2: HF cut-off values according to guidelines and recommendations that were published at the time of this survey. The classification 
into acute or chronic HF was taken from the statements in these publications. 
 
Guideline/Recommendation BNP NT-proBNP COR, LOE Reference 
Acute and chronic HF 
ESC guidelines 2008 Rule-out:     <100 ng/L 
Grey zone:  100-400 ng/L 
Rule-in:       >400 ng/L 
Rule-out:     <400 ng/L 
Grey zone:  100-2000 ng/L 




ACC/AHA guidelines 2009 Not stated Not stated IIa, A [13] 
ACCF/AHA guidelines 2013 Not stated Not stated I, A [14] 
ACC/AHA/HFSA guideline 
2017, focused update 
Not stated Not stated I [15] 
Chronic HF 
NICE national clinical 
guideline 2010 (UK) 
Rule-out <100 ng/L 
100-400 ng/L* 
>400 ng/L# 
Rule-out: <400 ng/L 
400-2000 ng/L*  
>2000 ng/L# 
n.a. [16] 
ESC guidelines 2012  Rule-out <35 ng/L Rule-out <125 ng/L IIa, C [11] 
ESC guidelines 2016 Rule-out <35 ng/L Rule-out <125 ng/L (essential initial 
investigation) 
[9] 
NICE national clinical 
guideline update 2018 (UK) 
NT-proBNP is favored Rule-out: <400 ng/L 
400-2000 ng/L*  
>2000 ng/L# 
n.a. [17] 
ESC/HFA position paper/ 
practice guidance 2019 
For age <50 years 
Rule-out:     <35 ng/L 
Grey zone:  35-150 ng/L 
For age <50 years 
Rule-out:     <125 ng/L 
Grey zone:  125-600 ng/L 
n.a. [18] 
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Rule-in:       >150 ng/L Rule-in:       >600 ng/L              
Acute HF 
ESC recommendations 2012 Rule-out:     <100 ng/L 
Grey zone:  100-500 ng/L 
Rule-in:       >500 ng/L 
Rule-out: 300 ng/L 
Rule in <50y: 450 ng/L 
          50-75y: 900 ng/L 
             >75y: 1800 ng/L 
n.a. [10] 
ESC guidelines 2012 Rule-out <100 ng/L Rule-out <300 ng/L IIa, C [11] 
ESC guidelines 2016 Rule-out <100 ng/L Rule-out <300 ng/L I, A [9] 
ESC/HFA position paper/ 
practice guidance 2019 
For age <50 years 
Rule-out:     <100 ng/L 
Grey zone:  100-400 ng/L 
Rule-in:       >400 ng/L 
Rule-out <50y: 300 ng/L 
Rule in <50y: 450 ng/L 
          50-75y: 900 ng/L 
             >75y: 1800 ng/L 
n.a. [18] 
 
FDA cleared package 
inserts (summarized for the 
different assays) 
100 ng/L <75y: 125 ng/L 
>75y: 450 ng/L 
n.a.  
 
*Patients with these medium values should be referred to a transthoracic Doppler 2D echocardiography and specialist assessment within 6 weeks.  
#Patients with these high NP levels have a poor prognosis and should be referred to a transthoracic Doppler 2D echocardiography and specialist 
assessment within 2 weeks.  
COR, class of recommendation; LOE, level of evidence; ESC, European Society of Cardiology; ACC or ACCF, American College of Cardiology 
Foundation; AHA, American Heart Association; NICE, the National Institute for Health and Care Excellence; HFA, Heart Failure Association; y; 
years; FDA, Food and Drug Administration. 
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Figure legends: 
Figure 1: Methods used for BNP and NT-proBNP measurement. 
A: NT-proBNP was still the most widely used NP method with a clear preference for the 
Roche assay (58%). B: Twenty (7.5%) laboratories measured more than one NP and mostly 
combined NT-proBNP from with a BNP assay from the same or a different company. 
 
Figure 2: Flow chart for decision limits. 
There were 266 participants, who answered HF questions. Because some laboratories used 
more than one assay for BNP or NT-proBNP measurement, these participants were also able 
to answer questions concerning cut-offs for both, BNP and NT-proBNP. Thus, there were a 
maximum of 223 answers for NT-proBNP and a maximum of 61 answers for BNP possible. 
Since not all participants answered all questions, the number of responses is lower. 
*, ESC recommendation 2012; #, ESC/HFA 2019 position paper; §, FDA threshold stated in 
the package insert not differentiating between acute and chronic HF. 
 
Figure 3: Decision limits for rule-out acute HF 
A: The decision limits for NT-proBNP were less diverse than in the previous survey with the 
most frequent decision limit of 300 ng/L, which is stated in the ESC guidelines. B: For BNP 
there was a clear preference for the 100 ng/L decision limit, which is guideline conform. 
Diagonal lines in columns, decision limits as stated either in the ESC guidelines published 
2016. 
 
Figure 4: Source of rule-out protocol for natriuretic peptide 
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